In recent trading session, Humacyte Inc (NASDAQ:HUMA) saw 1.41 million shares changing hands at last check today with its beta currently measuring 1.35. Company’s recent per share price level of $8.69 trading at $0.54 or 6.63% at last check today assigns it a market valuation of $1.03B. That most recent trading price of HUMA’s stock is at a discount of -14.73% from its 52-week high price of $9.97 and is indicating a premium of 77.45% from its 52-week low price of $1.96. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 3.88 million shares which gives us an average trading volume of 3.13 million if we extend that period to 3-months.
For Humacyte Inc (HUMA), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.40. Splitting up the data highlights that, out of 2 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 1 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Humacyte Inc (NASDAQ:HUMA) trade information
Upright in the green today for gaining 6.63%, in the last five days HUMA remained trading in the green while hitting it’s week-highest on Friday, 07/26/24 when the stock touched $8.69 price level, adding 3.44% to its value on the day. Humacyte Inc’s shares saw a change of 205.99% in year-to-date performance and have moved 15.10% in past 5-day. Humacyte Inc (NASDAQ:HUMA) showed a performance of 73.80% in past 30-days. Number of shares sold short was 14.6 million shares which calculate 3.48 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 4.5 to the stock, which implies a fall of -93.11% to its recent value today. Analysts have been projecting 4 as a low price target for the stock while placing it at a high target of 5. It follows that stock’s current price would jump 53.97% in reaching the projected high whereas dropping to the targeted low would mean a gain of 53.97% for stock’s current value.
Humacyte Inc (HUMA) estimates and forecasts
Statistics highlight that Humacyte Inc is scoring comparatively lower than the scores of other players of the relevant industry. The company added 189.67% of value to its shares in past 6 months, showing an annual growth rate of 11.21% while that of industry is 15.60. Apart from that, the company came raising its revenue forecast for fiscal year 2024.
Humacyte Inc (NASDAQ:HUMA)’s Major holders
Insiders are in possession of 30.67% of company’s total shares while institution are holding 20.01 percent of that, with stock having share float percentage of 28.86%. Investors also watch the number of corporate investors in a company very closely, which is 20.01% institutions for Humacyte Inc that are currently holding shares of the company. BLACKROCK INC. is the top institutional holder at HUMA for having 4.79 million shares of worth $14.89 million. And as of 2024-03-31, it was holding 4.6304 of the company’s outstanding shares.
The second largest institutional holder is VANGUARD GROUP INC, which was holding about 4.02 million shares on 2024-03-31. The number of shares represents firm’s hold over 3.8867 of outstanding shares, having a total worth of $12.5 million.
